BPA for orladeyo and rapivab
Active Awarded Last action
- Contract number
- 36E79726A0015
- Awardee
-
Biocryst Pharmaceuticals Inc. UEI MGXADJ6SCLJ5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 39% complete
- IDV ceiling
- $93,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The VA's National Acquisition Center established a Blanket Purchase Agreement with Biocryst Pharmaceuticals Inc. on June 3, 2026, with a $93 million ceiling through June 2, 2027, for expedited procurement of ORLADEYO (berotralstat) and RAPIVAB (peramivir) across federal healthcare programs.
The BPA is a single-award vehicle established against the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB). Biocryst supplies two FDA-approved small-molecule drugs: ORLADEYO for hereditary angioedema and RAPIVAB for influenza treatment. Place of performance reflects federal healthcare system ordering nationwide.
No set-aside category applies. The BPA establishes terms for expedited ordering without a stated guaranteed minimum. Recent ordering activity under related vehicles shows significant customer demand: the VA's Veterans Integrated Service Network 20 issued a $379.9 million delivery order on October 1, 2024, for berotralstat HCL 150mg capsules, and the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $69.4 million delivery order on September 30, 2024, for peramivir supply through September 29, 2025. Those orders flow through Biocryst's parent GSA Schedule; the newly established BPA provides an additional procurement pathway for expedited federal healthcare acquisition of both products.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726A0015?
36E79726A0015 was awarded to Biocryst Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on June 3, 2026.
How much is contract 36E79726A0015 worth?
36E79726A0015's own ceiling is $93,000,000.
Who can order from contract 36E79726A0015?
36E79726A0015 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79726A0015 under another contract?
Yes. 36E79726A0015 is a blanket purchase agreement under 36F79721D0166, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79726A0015 competed?
The extent of competition for 36E79726A0015 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV